Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator

Author： Li Ting   Jiang Sen  

Publisher： Informa Healthcare

ISSN： 1388-0209

Source： Pharmaceutical Biology (Formerly International Journal of Pharmacognosy), Vol.48, Iss.2, 2010-02, pp. : 161-165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator

By Tkachuk Vsevolod A.   Plekhanova Olga S.   Parfyonova Yelena V.  

Canadian Journal of Physiology and Pharmacology, Vol. 87, Iss. 4, 2009-04 ,pp. : 231-251

NRC Research Press

Access to resources Recommend Favorite

Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin

By Dunbar S.D.   Ornstein D.L.   Zacharski L.R.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 9, 2000-09 ,pp. : 2085-2092

Informa Healthcare

Access to resources Recommend Favorite

New developments in the urokinase-type plasminogen activator system

By Rosenberg Steven  

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 6, 2001-12 ,pp. : 711-722

Informa Healthcare

Access to resources Recommend Favorite

Inhibitors of the Protease Domain of Urokinase-Type Plasminogen Activator

By  

Current Pharmaceutical Design, Vol. 8, Iss. 28, 2002-12 ,pp. : 2541-2558

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule inhibitors of urokinase-type plasminogen activator

By Rockway Todd W  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 6, 2003-06 ,pp. : 773-786

Informa Healthcare

Access to resources Recommend Favorite